Insulet to Preview New Clinical Data and Next Generation Omnipod® System at the American Diabetes Association’s 77th Scientific Sessions

Insulet will exhibit at this year’s Scientific Session at Booth Location 507 and have four poster presentations to share new clinical data supporting the benefits of both its current Omnipod System, as well as its Omnipod Horizon Automated Glucose Control System.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), tubeless insulin pump technology with its Omnipod^® Insulin Management System (Omnipod System), today announced it will present new data for its Omnipod System including results from a hybrid closed-loop study utilizing the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System) involving a total of 24 pediatric patients from six to 18 years of age at the American Diabetes Association (ADA) 77th Scientific Sessions at the San Diego Convention Center June 9-13, 2017.

Shacey Petrovic, President and Chief Operating Officer, “We are deeply committed to delivering product innovation that provides our Podders with the technology and support they need to simplify their lives and ease the burden of diabetes. Petrovic went on to say, “With this compelling clinical data and groundbreaking new technology in development, we continue to provide our users and their health care providers with robust and simplified solutions to enhance quality of life and promote successful diabetes management.”

Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter Packard Children’s Hospital, Stanford University, and Principal Investigator, will be presenting the hybrid closed-loop study outcomes.